EUVIMEDEUVIMED entdecken
Crossref

Targeting the HNRNPA2B1/HDGF/PTN Axis to Overcome Radioresistance in Non-Small Cell Lung Cancer

Fushi Han, Shuzhen Chen, Kangwei Zhang, Kunming Zhang, Meng Wang, Peijun Wang iD

Antioxidants & Redox Signaling · 2025

DOI: 10.1089/ars.2024.0808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antioxidants & Redox Signaling, 2025. Verfasst von Fushi Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiation Tolerance, Heterogeneous-Nuclear Ribonucleoprotein Group A-B. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 85 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Radioresistance in non-small cell lung cancer (NSCLC) presents a major barrier to effective treatment. This study explores the molecular mechanisms underlying this resistance, focusing on the heterogeneous nuclear ribonucleoprotein A2B1/hepatoma-derived growth factor/pleiotrophin (HNRNPA2B1/HDGF/PTN) signaling pathway and its role in autophagy-dependent ferroptosis regulation. Our aim is to uncover how this pathway contributes to tumor cell survival under radiotherapy stress, thereby identifying potential therapeutic targets to overcome radioresistance.

Results

We developed radiotherapy-resistant lung cancer cell lines and assessed their proliferation and migration capabilities through Cell Counting Kit-8 and Transwell assays, respectively. Single-cell RNA sequencing revealed significant differences in gene expression profiles between radioresistance and radiation-sensitive cells. Functional studies, including immunofluorescence, flow cytometry, and biochemical staining, confirmed that radioresistance was associated with enhanced autophagy and altered ferroptosis. Furthermore, HNRNPA2B1 knockdown reduced the expression of Ki67 and proliferating cell nuclear antigen, markers of proliferation, in a mouse tumor model. In addition, modulation of HNRNPA2B1 affected protein interactions and N6-methyladenosine RNA modifications, as demonstrated by reverse transcription–quantitative polymerase chain reaction, Western blot, and methylation RNA immunoprecipitation–quantitative PCR. Innovation: This study provides new insights into how the HNRNPA2B1/HDGF/PTN pathway promotes radioresistance by influencing autophagy-dependent ferroptosis. This mechanism represents a potential vulnerability that could be therapeutically targeted to improve radiotherapy efficacy in lung cancer.

Conclusion

Our findings demonstrate that the HNRNPA2B1/HDGF/PTN signaling pathway plays a crucial role in sustaining radioresistant phenotypes by modulating autophagy and ferroptosis. Targeting this pathway may enhance the therapeutic response in NSCLC, offering a novel strategy to combat treatment resistance. Antioxid. Redox Signal. 43, 189–214.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiation ToleranceHeterogeneous-Nuclear Ribonucleoprotein Group A-BIntercellular Signaling Peptides and ProteinsCytokinesHumansAnimalsMiceSignal TransductionAutophagyCell Line, TumorCell ProliferationFerroptosisGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

HNRNPA2B1 signalingautophagyferroptosislung cancerradioresistance

Substanzen

Heterogeneous-Nuclear Ribonucleoprotein Group A-BIntercellular Signaling Peptides and ProteinsCytokineshnRNP A2

Autor:innen und Institutionen

  • Department of Medical Imaging, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Institute of Medical Imaging Artificial Intelligence, Tongji University School of Medicine, Shanghai, China.
  • Department of Nuclear Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Department of Internal Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Department of Radiotherapy, Tongji Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.

ORCID-Profile: Peijun Wang

Zitieren

APA

Han, F., Chen, S., Zhang, K., Zhang, K., Wang, M., & Wang, P. (2025). Targeting the HNRNPA2B1/HDGF/PTN Axis to Overcome Radioresistance in Non-Small Cell Lung Cancer. Antioxidants & Redox Signaling. https://doi.org/10.1089/ars.2024.0808

Vancouver

Han F, Chen S, Zhang K, Zhang K, Wang M, Wang P. Targeting the HNRNPA2B1/HDGF/PTN Axis to Overcome Radioresistance in Non-Small Cell Lung Cancer. Antioxidants & Redox Signaling. 2025. doi:10.1089/ars.2024.0808

BibTeX
@article{Han2025,
  author = {Han, Fushi and Chen, Shuzhen and Zhang, Kangwei and Zhang, Kunming and Wang, Meng and Wang, Peijun},
  title = {Targeting the HNRNPA2B1/HDGF/PTN Axis to Overcome Radioresistance in Non-Small Cell Lung Cancer},
  journal = {Antioxidants & Redox Signaling},
  year = {2025},
  doi = {10.1089/ars.2024.0808}
}
Kostenlos starten →